Executive Order Accelerating Medical Treatments for Serious Mental Illness
(April 18, 2026)

President Trump issued an executive order directing federal agencies to accelerate the development and availability of treatments for serious mental illness, with a focus on psychedelic therapies, including ibogaine. The order instructs the Food and Drug Administration (FDA) to prioritize review of qualifying therapies through the National Priority Voucher Program and to facilitate patient access under the Right to Try Act, including coordination with the Drug Enforcement Administration (DEA) on Schedule I handling authorizations. It also directs the Department of Health and Human Services (HHS) to allocate at least $50 million in existing funds through the Advanced Research Projects Agency for Health to support state-led initiatives and related research efforts. Additional provisions call for coordination among HHS, FDA, the Department of Veterans Affairs, and the private sector to expand clinical trial participation, improve data sharing, and support real-world evidence generation. The order further instructs the Attorney General, in consultation with HHS, to expedite review of therapies containing Schedule I substances following successful Phase 3 clinical trials, with rescheduling to proceed as appropriate for approved products.

Read Executive Order

Proclamation Adjusting Imports on Pharmaceuticals and Pharmaceutical Ingredients Into the United States
(April 2, 2026)

President Donald Trump signed a proclamation stating that U.S. reliance on imported pharmaceuticals and active pharmaceutical ingredients poses a threat to national security due to supply chain vulnerabilities.

The proclamation imposes tariffs of up to 100 percent on imported patented drugs and active pharmaceutical ingredients, while offering reduced or zero tariffs for companies that commit to onshoring production or enter into Most-Favored-Nation pricing agreements. It also directs federal agencies to negotiate trade and pricing agreements with key allies to support domestic manufacturing. Certain products, including orphan drugs and advanced therapies, are exempt from the tariffs, and generic drugs and their ingredients are not currently affected. The policy establishes monitoring and enforcement mechanisms to ensure compliance with onshoring commitments. Overall, the proclamation is intended to reduce reliance on foreign supply chains and strengthen domestic pharmaceutical production in support of national and public health security.

Read Proclamation

Executive Order Ending Certain Tariff Actions
(February 20, 2026)

President Trump issued an executive order terminating certain additional ad valorem duties previously imposed under the International Emergency Economic Powers Act (IEEPA). The order ends tariff actions implemented through several earlier executive orders addressing issues such as illicit drug trafficking, trade imbalances, and national security concerns involving specific foreign governments. Federal agencies are directed to cease collecting these additional duties and take steps to modify the Harmonized Tariff Schedule of the United States as needed. The order does not affect other tariffs imposed under Section 232 or Section 301 authorities and leaves in place other trade measures announced the same day, including the suspension of duty-free de minimis treatment and a temporary import surcharge.

Read Executive Order

Executive Order Continuing the Suspension of Duty-Free De Minimis Treatment for All Countries
(February 20, 2026)

President Trump issued an executive order continuing the suspension of the duty-free de minimis exemption for low-value imports. The order requires duties to be collected on shipments that would previously have qualified for duty-free treatment under 19 U.S.C. 1321, including many small parcels entering the United States through international postal networks. Transportation carriers must now collect and remit duties to U.S. Customs and Border Protection (CBP), and shipments must include declarations of value and country of origin. The policy builds on earlier executive orders addressing illicit drug trafficking and supply chain vulnerabilities, particularly those involving synthetic opioids and imports from China.

Read Executive Order

Executive Order Addressing Addiction through the Great American Recovery Initiative
(January 29, 2026)

President Trump signed an executive order launching the Great American Recovery Initiative, a new White House–led effort to coordinate the federal response to substance use disorder. Framing addiction as a chronic, treatable disease with wide-ranging economic and social consequences, the order emphasizes the gap between the number of Americans who need treatment and those who receive it, and calls for a more unified, evidence-based national approach to treatment and recovery. The initiative is intended to complement the Administration’s drug-interdiction efforts by prioritizing treatment, recovery support, and public awareness.

Read Executive Order

Executive Order Increasing Medical Marijuana and Cannabidiol Research
(December 18, 2025)

President Trump signed an EO directing federal government expansion on research on medical marijuana and cannabidiol (CBD) to better inform patients and clinicians about their safety, efficacy, and appropriate use. It calls for completing the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, modernizing the regulatory framework for hemp-derived cannabinoid products, and developing real-world evidence research models across HHS, FDA, CMS, and NIH to close gaps between widespread use and medical guidance.

Read Executive Order

Executive Order Ensuring Continued Accountability in Federal Hiring
(October 15, 2025)

President Trump issued an executive order increasing political oversight of federal hiring by placing senior appointees in charge of staffing decisions. The order requires agencies to establish “Strategic Hiring Committees” composed of senior political officials to approve new hires. It also mandates that agencies submit annual staffing plans within 60 days to align hiring with administrative priorities and reduce the size of the federal workforce. The order builds on the Administration’s “Merit Hiring Plan” and follows the creation of the “Schedule G” category, which allows certain politically aligned hires to be dismissed at will. The order exempts some positions, including those related to immigration enforcement, national security, and public safety, but would apply to agencies such as HHS, CMS, and FDA.

Read Executive Order

Executive Order Unlocking Cures for Pediatric Cancer with Artificial Intelligence
(September 30, 2025)

President Trump issued an executive order directing federal agencies to leverage artificial intelligence to accelerate the development of cures for pediatric cancer. The order builds on initiatives such as the Childhood Cancer Data Initiative (CCDI) and directs HHS and other agencies to expand the use of AI to improve diagnosis, treatment, and prevention of childhood cancers. Key actions include strengthening data infrastructure for AI analysis, improving clinical trial design and patient access, expanding investment in pediatric cancer research, and enhancing data sharing and interoperability while protecting patient privacy.

Read Executive Order

Executive Order Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve
(August 13, 2025)

President Trump issued an executive order directing the Department of Health and Human Services (HHS) to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with a six-month supply of active pharmaceutical ingredients (APIs) for the most critical medicines. The order is intended to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign supply chains. It also directs HHS to implement longer-term resilience measures, including updating the federal essential medicines list and establishing a second SAPIR repository. Read the official fact sheet here.

Read Executive Order

Executive Order Accelerating Federal Permitting of Data Center Infrastructure
(July 23, 2025)

President Trump issued an executive order aimed at accelerating the development of artificial intelligence data centers and related infrastructure by easing federal permitting requirements. The order streamlines environmental reviews, encourages the use of federal land for qualifying projects, and rescinds Executive Order 14141 issued by the previous administration. It also directs federal agencies to identify financial incentives that could support projects deemed important for national security and economic growth. The order defines qualifying projects as those involving at least $500 million in investment or requiring more than 100 megawatts of power and directs agencies to use FAST-41 procedures to expedite federal permitting.

Read Executive Order

Executive Order Preventing Woke AI in the Federal Government
(July 23, 2025)

President Trump issued an executive order directing federal agencies to procure only artificial intelligence models that adhere to principles described as “truth-seeking and ideological neutrality.” The order prohibits the use of AI systems that incorporate concepts associated with diversity, equity, and inclusion (DEI), including references to critical race theory, systemic racism, or gender ideology. Federal agencies are required to revise procurement contracts and implement procedures to ensure compliance with the order within 90 days.

Read Executive Order

Executive Order Implementing the General Terms of the U.S.–UK Economic Prosperity Deal
(June 16, 2025)

President Trump issued an executive order implementing the U.S.–U.K. Economic Prosperity Deal. The agreement adjusts tariffs and establishes tariff-rate quotas on selected imports from the United Kingdom, including automobiles, steel, aluminum, aerospace products, pharmaceuticals, and other industrial goods. The order places particular emphasis on pharmaceuticals and active pharmaceutical ingredients (APIs), outlining plans for preferential trade treatment. This preferential treatment is contingent on the outcome of a national security investigation under Section 232 of the Trade Expansion Act and the United Kingdom’s compliance with supply chain security standards. Read the official fact sheet here.

Read Executive Order

Executive Order Restoring Gold Standard Science
(May 23, 2025)

President Trump issued an executive order intended to strengthen public trust in federal science by promoting transparency, rigor, and objectivity in the use of scientific information. The order directs federal agencies to adopt standards described as “Gold Standard Science,” emphasizing reproducibility, peer review, transparency, acknowledgment of uncertainty, and the elimination of conflicts of interest. Agencies are required to update their scientific integrity policies to reflect these principles and communicate those policies publicly.

Read Executive Order

Executive Order Modifying Reciprocal Tariff Rates to Reflect Discussions With the People’s Republic of China
(May 12, 2025)

President Trump issued an executive order temporarily modifying reciprocal tariff rates on imports from the People’s Republic of China, including Hong Kong and Macau. The order suspends certain additional tariffs for 90 days beginning May 14, 2025. During this period, the additional ad valorem duty on Chinese imports will be reduced to 10 percent from previously higher rates. The order also lowers tariffs on low-value imports associated with the synthetic opioid supply chain from 120 percent to 54 percent while maintaining a $100 per-item duty.

Read Executive Order

Executive Order Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
(May 12, 2025)

President Trump issued an executive order directing federal agencies to pursue policies ensuring that Americans do not pay more for prescription drugs than consumers in other developed countries. The order instructs the Secretary of Health and Human Services to communicate “most-favored-nation” price targets to pharmaceutical manufacturers within 30 days and to explore mechanisms allowing patients to purchase medications directly at the lowest global price. If manufacturers do not implement significant pricing changes, the Administration indicates it may pursue regulatory actions, expanded drug importation pathways, enforcement against anti-competitive practices, or other policy measures. The order also directs the Departments of Commerce and State to address foreign government pricing policies that the Administration argues shift pharmaceutical development costs onto American consumers. Read the official fact sheet here.

Read Executive Order

Executive Order Increasing Efficiency at the Office of the Federal Register
(May 9, 2025)

President Trump issued an executive order directing the Office of the Federal Register to work with the Director of the Government Publishing Office to reduce delays in the publication of regulatory actions, including by modernizing computer systems and eliminating unnecessary administrative processes. The order notes that executive departments and agencies are currently charged between $151 and $174 per text column to publish rules in the Federal Register. It directs the Office to ensure that publication fees more accurately reflect the actual costs of publication and account for efficiencies achieved as a result of the order.

Read Executive Order

Executive Order Regulatory Relief to Promote Domestic Production of Critical Medicines
(May 5, 2025)

President Trump issued an executive order aimed at strengthening the United States’ domestic pharmaceutical supply chain by accelerating and simplifying regulatory processes affecting drug manufacturing. The order directs the Food and Drug Administration (FDA), Environmental Protection Agency (EPA), and U.S. Army Corps of Engineers to review and revise relevant regulations within 180 days to accelerate facility construction, reduce permitting delays, and clarify compliance requirements for domestic manufacturers. The FDA is specifically instructed to improve the predictability and timeliness of inspections, enhance enforcement of data reporting requirements, and provide clearer regulatory guidance. The EPA is designated as the lead agency for coordinating environmental permitting. The Administration states that the policy is intended to strengthen domestic pharmaceutical manufacturing capacity, improve national security, and reduce reliance on foreign supply chains. Read the official fact sheet here.

Read Executive Order

Executive Order Improving Safety and Security of Biological Research
(May 5, 2025)

President Trump issued an executive order aimed at strengthening the safety and security of biological research. The order halts federal funding for certain gain-of-function research, particularly research conducted in foreign countries with limited oversight, and directs agencies to tighten domestic safeguards. It calls for stronger enforcement mechanisms, increased transparency, and more rigorous screening of federally funded biological research projects. The order also establishes new conditions for federally funded research grants, including enhanced compliance and reporting requirements, with penalties for violations. Read the official fact sheet here.

Read Executive Order

Executive Order Unleashing America’s Offshore Critical Minerals and Resources
(April 24, 2025)

President Trump issued an executive order directing a whole-of-government effort to accelerate the exploration, development, and processing of critical mineral resources in offshore areas. Citing national security and economic priorities, the order seeks to reduce reliance on foreign adversaries for materials essential to key industries. The directives include streamlining permitting processes, expanding geological mapping and resource extraction, investing in domestic mineral processing capacity, and strengthening international collaborations. The policy may have implications for healthcare supply chains, as many medical devices and pharmaceutical products rely on materials derived from critical minerals.

Read Executive Order

Executive Order Ensuring Commercial, Cost-Effective Solutions in Federal Contracts
(April 16, 2025)

President Trump issued an executive order directing federal agencies to prioritize the procurement of commercially available products and services rather than custom or non-commercial solutions. Agencies must review current and pending solicitations, justify the use of non-commercial products, and report compliance to the Office of Management and Budget (OMB). The order also increases oversight of federal procurement by requiring approval from senior procurement officials—and in some cases OMB—before certain purchases may proceed. The policy aims to reduce waste, improve efficiency, and promote cost-effective federal spending. The order may also affect healthcare agencies by influencing procurement processes for medical products and health technology.

Read Executive Order

Executive Order Ensuring National Security and Economic Resilience Through Section 232 Actions on Processed Critical Minerals and Derivative Products
(April 15, 2025)

President Trump issued an executive order directing an investigation under Section 232 of the Trade Expansion Act into whether U.S. reliance on imported critical minerals threatens national security. These materials are essential for defense, energy, technology, and other key sectors of the economy. The order calls for a review of import sources, supply chains, domestic production capacity, and potential policy responses. The Secretary of Commerce is directed to submit a final report with recommendations within 180 days. The findings of this investigation may also have implications for healthcare supply chains, as many medical devices and technologies rely on processed critical minerals.

Read Executive Order

Executive Order Lowering Drug Prices by Once Again Putting Americans First
(April 15, 2025)

President Trump signed an executive order expanding efforts to reduce prescription drug costs for Americans. The order builds on earlier initiatives and directs federal agencies to enhance the Medicare Drug Price Negotiation Program by prioritizing high-cost drugs and improving pricing transparency. It also instructs the Department of Health and Human Services (HHS) to pursue actions aimed at lowering medication costs for seniors, improving oversight of Medicaid drug payment policies, and increasing competition through faster approval of generics, biosimilars, and over-the-counter conversions. The order further calls for greater transparency in pharmacy benefit manager (PBM) compensation and streamlining drug importation pathways to improve access to lower-cost medicines. Read the fact sheet here.

Read Executive Order

Executive Order Amendment to Reciprocal Tariffs and Updated Duties as Applied to Low-Value Imports From the People’s Republic of China
(April 9, 2025)

President Trump issued an executive order amending his earlier reciprocal tariff policy in response to retaliatory tariffs announced by China. The order increases tariffs on certain Chinese goods from 34 percent to 84 percent and raises duties on low-value imports from China by 90 percent. The Administration stated that these measures are intended to address the U.S. trade deficit and protect national security interests. The order follows China’s announcement of a 34 percent tariff on U.S. goods, scheduled to take effect on April 10, 2025. The updated tariff measures took effect April 9, 2025.

*Note: Later on April 9, President Trump announced that tariffs on Chinese imports would increase to 125 percent effective immediately, as described here. The Administration also announced a 90-day pause and a temporary reduction of reciprocal tariffs to 10 percent for 75 countries that had not imposed retaliatory tariffs and were engaged in negotiations with the United States.

Read Executive Order

Executive Order Further Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People’s Republic of China as Applied to Low-Value Imports
(April 2, 2025)

President Trump issued an executive order addressing low-value imports from China linked to the synthetic opioid supply chain. The order eliminates the de minimis exemption for goods valued at $800 or less, effective May 2, 2025, making those shipments subject to new duties. The policy targets shipping practices that allow illicit substances to be concealed within small import packages. Under the order, affected shipments will be subject to either a 30 percent ad valorem duty or a specific duty ranging from $25 to $50 per item depending on the date of entry. The order also requires carriers transporting these imports to report shipments to U.S. Customs and Border Protection, remit applicable duties, and maintain an International Carrier Bond. The Administration states that the policy is intended to reduce the flow of synthetic opioids into the United States while addressing trade imbalances. Read the fact sheet here.

Read Executive Order

Executive Order Regulating Imports with a Reciprocal Tariff to Rectify Trade Practices that Contribute to Large and Persistent Annual United States Goods Trade Deficits
(April 2, 2025)

President Trump issued an executive order declaring a national emergency related to persistent U.S. trade deficits and establishing a reciprocal tariff policy. Beginning April 5, a 10 percent duty will be imposed on all imports, with country-specific tariff rates scheduled to take effect on April 9. The order cites the U.S. goods trade deficit—reported at $1.2 trillion in 2024—as evidence that current trade practices have weakened domestic manufacturing and increased reliance on foreign supply chains in sectors important to national security and the broader economy. The order also authorizes the President to adjust tariffs in response to retaliatory measures by trading partners or other changes in trade conditions. Certain goods, including pharmaceuticals, minerals, semiconductors, and energy products, are exempt from the policy. Read the fact sheet here.

Read Executive Order

Executive Order Establishing the United States Investment Accelerator
(March 31, 2025)

President Trump issued an executive order establishing the United States Investment Accelerator, a federal initiative designed to facilitate large-scale domestic investment projects. The initiative is intended to coordinate federal agencies in supporting strategic investments by streamlining regulatory review, identifying federal resources, and helping projects navigate permitting and approval processes. The order aims to accelerate economic development and promote domestic manufacturing and infrastructure investment by improving coordination across federal agencies. Read the fact sheet here.

Read Executive Order

Executive Order: Exclusions From Federal Labor-Management Relations Programs
(March 27, 2025)

President Trump issued an executive order outlining exclusions from the Federal Labor-Management Relations Statute for certain federal agencies, citing national security considerations. Agencies identified in the order include the Centers for Medicare and Medicaid Services (CMS), the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and several other federal entities. Under the order, these agencies are exempt from certain collective bargaining requirements, grievance procedures, and union participation provisions. The Administration stated that the change is intended to allow agencies with national security, public health, and emergency response responsibilities to operate without delays that could arise from labor-management negotiations. Read the fact sheet here.

Read Executive Order

Executive Order Eliminating Waste and Saving Taxpayer Dollars by Consolidating Procurement
(March 20, 2025)

President Trump issued an executive order directing the consolidation of federal procurement functions within the General Services Administration (GSA) to reduce waste and inefficiency across government agencies. The consolidation focuses on common goods and services, such as office supplies and facilities management, as well as information technology purchases including computers and software. By centralizing procurement through GSA, individual agencies will no longer independently acquire these goods and services. The order aims to streamline operations and reduce costs across federal agencies, including CMS, HHS, CDC, and others.

Read Executive Order

Presidential Memorandum Strengthening the Suitability and Fitness of the Federal Workforce
(March 20, 2025)

President Trump issued a memorandum delegating to the Director of the Office of Personnel Management (OPM) the authority to make final determinations regarding the suitability of federal employees based on post-appointment conduct and actions. The Director is also directed to propose any necessary changes to regulations in Title 5 of the Code of Federal Regulations to guide these determinations. Under the memorandum, the Director may instruct the head of an agency to remove an employee who does not meet the suitability standards established under OPM rules. Agencies must comply with such instructions within five business days. The memorandum also states that it does not alter the existing legal authorities of federal agencies or create enforceable rights and is intended to operate consistent with current law.

Read Memorandum

Executive Order Stopping Waste, Fraud, and Abuse by Eliminating Information Silos
(March 20, 2025)

President Trump issued an executive order aimed at combating waste, fraud, and abuse within federal agencies by eliminating information silos and promoting data sharing. Agency heads are directed to ensure that federal officials have access to unclassified data and systems to identify waste or fraud within 30 days. The order calls for expanded sharing and consolidation of records both within and between federal agencies. It also directs the federal government to obtain access to data from state programs that receive federal funding. The executive order may affect programs administered by HHS, CMS, CDC, and other health-related agencies. Read the fact sheet.

Read Executive Order

Executive Order Continuing the Reduction of the Federal Bureaucracy
(March 14, 2025)

President Trump signed an executive order aimed at further reducing the federal bureaucracy. The order eliminates several non-statutory components of various government entities, including the Community Development Financial Institutions Fund (CDFI). While not directly focused on healthcare, the reduction of the CDFI could indirectly affect healthcare and public health programs. The fund provides financial assistance to community-based organizations, many of which are involved in health-related initiatives.

Read Executive Order

Executive Order Designating English as the Official Language of the United States
(March 1, 2025)

President Trump signed an executive order establishing English as the official language of the United States. By designating English as the sole official language, the order revokes Executive Order 13166 on improving access for persons with limited English proficiency (LEP), though it does not require agencies to discontinue multilingual services or documents. Organizations, including healthcare entities, may continue to offer multilingual services, but they are no longer federally mandated to do so. The Attorney General was directed to rescind previous policy guidance and issue updated guidance consistent with applicable law.

Read Executive Order

Executive Order Implementing the President’s “Department of Government Efficiency” Cost Efficiency Initiative
(February 26, 2025)

This executive order directs agency heads to develop a system to record every payment issued under covered contracts and grants, along with a brief written justification submitted by the approving agency employee. Agencies are also directed to review existing contracts and grants and terminate or modify them where appropriate to reduce federal spending or reallocate resources in support of the Administration’s policy priorities. Contracting policies, procedures, and personnel will also be reviewed as part of the initiative.

Read Executive Order

Executive Order Making America Healthy Again by Empowering Patients With Clear, Accurate, and Actionable Healthcare Pricing Information
(February 25, 2025)

This executive order directs the Secretary of the Treasury, the Secretary of Labor, and the Secretary of Health and Human Services to take “all necessary and appropriate action to rapidly implement and enforce the healthcare price transparency regulations issued pursuant to Executive Order 13877,” signed in 2019. Within 90 days, the order calls for action to:

• Require disclosure of the actual prices of items and services rather than estimates
• Issue updated guidance or proposed regulatory action ensuring pricing information is standardized and easily comparable across hospitals and health plans
• Update enforcement policies to ensure compliance with transparent reporting of complete, accurate, and meaningful pricing data

Read Executive Order

Executive Order Ending Taxpayer Subsidization of Open Borders
(February 19, 2025)

This executive order aims to prevent individuals without legal immigration status from accessing taxpayer-funded resources. The action follows a Congressional Budget Office estimate that policies associated with the Biden Administration’s immigration approach—including Medicaid-funded emergency services provided to certain noncitizens—have cost federal and state taxpayers more than $16.2 billion. The order signals a potential shift in healthcare policy by tightening eligibility rules and limiting access to taxpayer-funded health services. Read the fact sheet.

Read Executive Order

Executive Order Commencing the Reduction of the Federal Bureaucracy
(February 19, 2025)

This executive order seeks to reduce the size of the federal government in order to enhance accountability, reduce waste, and promote innovation. It terminates several federal councils and advisory committees, including the CMS Health Equity Advisory Committee and the HHS Secretary’s Advisory Committee on Long COVID, as well as the Presidential Management Fellows program. The order also directs certain government entities to reduce their functions to the minimum presence and activity required by law. Within 30 days, agencies must submit a list of additional federal entities and advisory committees that may be suitable for termination. Read the fact sheet.

Read Executive Order

Executive Order Ensuring Lawful Governance and Implementing The President’s “Department Of Government Efficiency” Deregulatory Initiative (February 19, 2025)

This order directs agency heads, in coordination with their DOGE team leads and the Office of Management and Budget (OMB), to review all regulations subject to their jurisdiction for consistency with law and Trump Administration policy, prioritizing rules that impose heavy costs. A Unified Agenda will be developed to rescind and/or modify regulations that are inconsistent with law or the Trump Administration’s policy. Read the fact sheet.

Read Executive Order

Executive Order Expanding Access to In Vitro Fertilization (February 18, 2025)

This executive order aims to expand access to IVF for Americans. The order focuses on reducing the financial barriers associated with IVF treatments, which cost between $12,000 and $25,000 per cycle and insurance companies often do not fully cover. The plan directs policy recommendations to ensure reliable access to IVF, lower out-of-pocket costs, and address policies that increase treatment expenses. Read the fact sheet.

Read Executive Order

Executive Order Keeping Education Accessible and Ending COVID-19 Vaccine Mandates In Schools (February 15, 2025)

This executive order aims to end COVID-19 vaccine mandates in schools, citing that such mandates infringe on personal freedoms and parental authority. It prohibits federal funds from supporting, directly or indirectly, educational institutions that require vaccination for in-person attendance. The Secretary of Education is tasked with issuing guidelines to ensure compliance with legal obligations and developing a plan to eliminate vaccine mandates within 90 days.

Read Executive Order

Executive Order Establishing The President’s Make America Healthy Again Commission (February 13, 2025)

President Trump declared that it “shall be the policy of the Federal Government to aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases. To do so, executive departments and agencies (agencies) that address health or healthcare must focus on reversing chronic disease.” The order calls for the establishment of the President’s Make America Healthy Again Commission (Commission), chaired by the Secretary of Health and Human Services (Chair), with the Assistant to the President for Domestic Policy serving as Executive Director (Executive Director).

Read Executive Order

Executive Order Protecting Children from Chemical and Surgical Mutilation (January 28, 2025)

President Trump has directed the FDA and HHS to take steps against gender-affirming care for minors.  President Trump is seeking to block transgender children from accessing transition-related care. Measures include directing the FDA to investigate companies offering transition-related medical products, urging the DOJ to consider prosecuting healthcare providers, and blocking federal funding for hospitals and entities that provide such care. The order also mandates HHS to review and potentially amend policies related to gender-affirming care and withdraw guidance protecting transgender minors’ privacy. This reflects a broader push to limit transgender healthcare for minors across the United States.

Read Executive Order

Executive Order Enforcing the Hyde Amendment (January 24, 2025)

States that it is the “policy of the United States, consistent with the Hyde Amendment, to end the forced use of Federal taxpayer dollars to fund or promote elective abortion” and directs the Office of Management and Budget to promulgate guidance to the heads of executive departments and agencies related to implementation of this policy.

Read Executive Order

Executive Order Establishing President’s Council Of Advisors On Science And Technology (January 23, 2025)

Reestablishes “the President’s Council of Advisors on Science and Technology to unite the brightest minds from academia, industry, and government to guide our Nation through this critical moment by charting a path forward for American leadership in science and technology.”

Read Executive Order

Executive Order Removing Barriers to American Leadership in Artificial Intelligence (January 23, 2025)

Undertaken with the goal of making the United States the “global leader in AI,” the order emphasizes the importance of developing AI systems that are “free from ideological bias or engineered social agendas.”  Read Applied Policy’s analysis here.

Read Executive Order

Regulatory Freeze Pending Review (January 20, 2025)

This memorandum directs all executive departments and agencies to freeze the implementation of new rules and regulations until they undergo review by agency heads appointed after January 20, 2025. It also required the immediate withdrawal of any unpublished rules and the postponement of the effective date for rules already published, to allow for a 60-day review period. The goal is to ensure that new regulations align with the administration’s priorities and policies.

Read Executive Order

Executive Order Establishing the Department of Government Efficiency (January 20, 2025)

Establishes the Department of Government Efficiency to implement the President’s DOGE Agenda, by modernizing Federal technology and software to maximize governmental efficiency and productivity.

Read Executive Order

Executive Order Withdrawing the United States from the World Health Organization
(January 20, 2025)

President Trump announced plans to withdraw the United States from the World Health Organization (WHO) on January 20, 2025. The executive order states that the Secretary of State will also “cease negotiations on the WHO Pandemic Agreement and the amendments to the International Health Regulations,” and that actions taken to implement those agreements will have no binding force on the United States.

Read Executive Order

Executive Order Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government
(January 20, 2025)

This executive order states that it is the policy of the United States to recognize two sexes, male and female, and that these sexes are not changeable and are grounded in fundamental and incontrovertible reality. It instructs federal agencies to remove statements, policies, regulations, forms, communications, or other internal and external messages that promote or otherwise inculcate what the order describes as “gender ideology.”

Read Executive Order

Executive Order Protecting the Meaning and Value of American Citizenship
(January 20, 2025)

This order asserts that children may only receive U.S. citizenship if at least one parent is a U.S. citizen or lawful permanent resident.

This could affect healthcare access for children born in the United States to parents without legal status, as they may encounter difficulties obtaining citizenship and associated healthcare benefits. Several organizations have filed lawsuits challenging the constitutionality of the order (find one example here), and courts in Maryland and Washington have issued temporary injunctions. In a series of filings (here, here, and here) the Trump Administration has asked the Supreme Court to block current injunctions.

Read Executive Order

Immediate Pause on Issuing Documents and HHS Public Communications
(January 21, 2025)

Acting HHS Secretary Dorothy Fink issued an agency-wide memorandum directing leaders across HHS to refrain from publicly releasing documents or communications—including regulations and press releases—until they had been reviewed and approved by a presidential appointee. The directive included an exception for emergencies and matters critical to health and safety. The pause was initially scheduled to remain in effect through February 1, 2025. As of February 7, some communications had resumed.

Read Memo